taurine has been researched along with Anoxemia in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought in our cross-sectional study to investigate the role of metabolic/hypoxial axis in the development of tamoxifen (TMX) resistance in BC patients." | 8.12 | Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer. ( Azzam, HN; El-Demerdash, E; El-Derany, MO; Faheim, RM; Helal, GK; Wahdan, SA, 2022) |
| " In this study we analyzed resected tissue metabolites using capillary electrophoresis-mass spectrometry and found that tissue hypotaurine levels strongly and positively correlated with glioma grade." | 7.83 | Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling. ( Chu, H; Feldman, MJ; Gao, P; Heiss, JD; Li, G; Liu, H; Liu, Y; Nesvick, CL; Sizdahkhani, S; Tang, L; Tian, J; Xu, G; Yang, C; Yang, F; Zhao, S; Zhuang, Z, 2016) |
| "The glial cells were primarily cultured and divided into three groups, the control group, hypoxia group, and hypoxia + taurine group." | 7.81 | [Taurine inhibited the apoptosis of glial cells induced by hypoxia]. ( Huang, H; Huang, Z; Wang, Q, 2015) |
| "This study was conducted to evaluate the effects of dietary taurine, as a feed additive, on the hypoxia-tolerance and growth performance of the juvenile grass carp Ctenopharyngodon idellus, one of the most important and intensively cultured freshwater fish, with the largest production in China." | 7.79 | Dietary taurine can improve the hypoxia-tolerance but not the growth performance in juvenile grass carp Ctenopharyngodon idellus. ( Huang, J; Liang, G; Liu, Y; Tian, L; Yang, H, 2013) |
| "It was found that preliminary treatment by amino acid taurine protected rats from lipid peroxidation intensification (expressed in terms of malondialdehyde and conjugated dienes contents) in the liver, brain and heart under acute severe normobaric hypoxic hypoxia." | 7.70 | [The antioxidant action of taurine in acute hypoxic hypoxia]. ( Bystriukov, VO; Kharlamova, OM; Man'kovs'ka, IM; Seredenko, MM; Vavilova, HL, 1998) |
| "The releases of endogenous glutamate, aspartate, GABA and taurine from hippocampal slices from 7-day-, 3-, 12-, and 18-month-old mice were investigated under cell-damaging conditions using a superfusion system." | 7.70 | Release of endogenous glutamate, aspartate, GABA, and taurine from hippocampal slices from adult and developing mice under cell-damaging conditions. ( Oja, SS; Saransaari, P, 1998) |
| "The effects of hypoxic hypoxia on the concentration of taurine in right ventricles was studied in the hearts of male CF1 mice caged individually and maintained for 16 hr per day in a hypobaric chamber evacuated to an air pressure of 307 mm Hg." | 7.67 | Effect of hypoxic hypoxia on taurine concentrations in ventricles of mouse hearts. ( Eldridge, SA; Hilton, FK; Hilton, MA, 1985) |
| "The effect of the intracerebroventricular (ICV) administration of taurine on amnesia, convulsions and death caused by hypoxia was investigated in mice." | 7.67 | Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia. ( Bartolini, A; Bennardini, F; Franconi, F; Ghelardini, C; Giotti, A; Malcangio, M; Malmberg-Aiello, P, 1989) |
| "Taurine is a β-amino acid known to regulate cardiac function in other animal models but its role in fish has not been well characterized." | 5.91 | Taurine depletion impairs cardiac function and affects tolerance to hypoxia and high temperatures in brook char (Salvelinus fontinalis). ( Buldo, EC; Cockshutt, A; Dixon, TM; El, N; Lamarre, SG; MacCormack, TJ; McGaw, SP; Morash, AJ; Otley, NA; Pabody, CM; Parker, KS; Rhyno, EM; Savoie, M, 2023) |
| "Taurine is an inhibitory neurotransmitter and is one of the most abundant amino acids present in the mammalian nervous system." | 5.39 | The mechanism of taurine protection against endoplasmic reticulum stress in an animal stroke model of cerebral artery occlusion and stroke-related conditions in primary neuronal cell culture. ( Chen, PC; Gharibani, PM; Ma, Z; Menzie, J; Modi, J; Pan, C; Prentice, H; Tao, R; Wu, JY, 2013) |
| "Taurine depletion was achieved by exposing isolated neonatal cardiomyocytes to medium containing the taurine analog beta-Alanine." | 5.31 | Beneficial effect of taurine depletion on osmotic sodium and calcium loading during chemical hypoxia. ( Kakhniashvili, D; Schaffer, SW; Solodushko, V, 2002) |
| "Taurine release was partially Ca2+-dependent in all cases." | 5.30 | Enhanced taurine release in cell-damaging conditions in the developing and ageing mouse hippocampus. ( Oja, SS; Saransaari, P, 1997) |
| "We sought in our cross-sectional study to investigate the role of metabolic/hypoxial axis in the development of tamoxifen (TMX) resistance in BC patients." | 4.12 | Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer. ( Azzam, HN; El-Demerdash, E; El-Derany, MO; Faheim, RM; Helal, GK; Wahdan, SA, 2022) |
| " The effects of USC-Exo on ferroptosis and lncRNA taurine-upregulated gene 1 (TUG1) were detected in hypoxia/reoxygenation (H/R)-treated human proximal tubular epithelial cells (HK-2)." | 4.12 | Exosomal lncRNA TUG1 derived from human urine-derived stem cells attenuates renal ischemia/reperfusion injury by interacting with SRSF1 to regulate ASCL4-mediated ferroptosis. ( Bi, Q; Sun, Z; Wang, W; Wu, J, 2022) |
| " In this study we analyzed resected tissue metabolites using capillary electrophoresis-mass spectrometry and found that tissue hypotaurine levels strongly and positively correlated with glioma grade." | 3.83 | Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling. ( Chu, H; Feldman, MJ; Gao, P; Heiss, JD; Li, G; Liu, H; Liu, Y; Nesvick, CL; Sizdahkhani, S; Tang, L; Tian, J; Xu, G; Yang, C; Yang, F; Zhao, S; Zhuang, Z, 2016) |
| "The glial cells were primarily cultured and divided into three groups, the control group, hypoxia group, and hypoxia + taurine group." | 3.81 | [Taurine inhibited the apoptosis of glial cells induced by hypoxia]. ( Huang, H; Huang, Z; Wang, Q, 2015) |
| "This study was conducted to evaluate the effects of dietary taurine, as a feed additive, on the hypoxia-tolerance and growth performance of the juvenile grass carp Ctenopharyngodon idellus, one of the most important and intensively cultured freshwater fish, with the largest production in China." | 3.79 | Dietary taurine can improve the hypoxia-tolerance but not the growth performance in juvenile grass carp Ctenopharyngodon idellus. ( Huang, J; Liang, G; Liu, Y; Tian, L; Yang, H, 2013) |
| "We investigated whether taurine indirectly protects neurons under hypoxia by affecting retinal Müller cells, which are known to play important roles in the regulation of retinal glutamate content." | 3.76 | Taurine buffers glutamate homeostasis in retinal cells in vitro under hypoxic conditions. ( Chang, H; Chen, F; Chen, K; Lang, H; Mi, M; Tang, Y; Wang, B; Wang, J; Wei, N; Xu, H; Yu, X; Yuan, J; Zhang, Q; Zhou, Y, 2010) |
| " Taurine may have been released by the tissues as a protective mechanism against hypoxia-induced inflammation, or in an attempt to maintain osmotic balance." | 3.74 | Taurine as a marker for foetal wellbeing? ( de Boo, HA; Harding, JE, 2007) |
| "The ventilatory response to hypoxia is influenced by the balance between inhibitory (GABA, glycine, and taurine) and excitatory (glutamate and aspartate) brainstem amino acid (AA) neurotransmitters." | 3.74 | Brainstem amino acid neurotransmitters and ventilatory response to hypoxia in piglets. ( Bancalari, E; Devia, CJ; Hehre, DA; Suguihara, C, 2008) |
| "The releases of endogenous glutamate, aspartate, GABA and taurine from hippocampal slices from 7-day-, 3-, 12-, and 18-month-old mice were investigated under cell-damaging conditions using a superfusion system." | 3.70 | Release of endogenous glutamate, aspartate, GABA, and taurine from hippocampal slices from adult and developing mice under cell-damaging conditions. ( Oja, SS; Saransaari, P, 1998) |
| "It was found that preliminary treatment by amino acid taurine protected rats from lipid peroxidation intensification (expressed in terms of malondialdehyde and conjugated dienes contents) in the liver, brain and heart under acute severe normobaric hypoxic hypoxia." | 3.70 | [The antioxidant action of taurine in acute hypoxic hypoxia]. ( Bystriukov, VO; Kharlamova, OM; Man'kovs'ka, IM; Seredenko, MM; Vavilova, HL, 1998) |
| " The purpose of this study was to test the hypothesis that a short period of hypoxia would affect release of excitatory and inhibitory amino acids during subsequent bicuculline-induced seizure." | 3.68 | Hypoxia increases extracellular concentrations of excitatory and inhibitory neurotransmitters in subsequently induced seizure: in vivo microdialysis study in the rabbit. ( Aquila, WJ; During, MJ; Ley, E; Tendler, D; Young, RS, 1992) |
| "The effect of the intracerebroventricular (ICV) administration of taurine on amnesia, convulsions and death caused by hypoxia was investigated in mice." | 3.67 | Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia. ( Bartolini, A; Bennardini, F; Franconi, F; Ghelardini, C; Giotti, A; Malcangio, M; Malmberg-Aiello, P, 1989) |
| "The effects of hypoxic hypoxia on the concentration of taurine in right ventricles was studied in the hearts of male CF1 mice caged individually and maintained for 16 hr per day in a hypobaric chamber evacuated to an air pressure of 307 mm Hg." | 3.67 | Effect of hypoxic hypoxia on taurine concentrations in ventricles of mouse hearts. ( Eldridge, SA; Hilton, FK; Hilton, MA, 1985) |
| "Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
| "Taurine is a β-amino acid known to regulate cardiac function in other animal models but its role in fish has not been well characterized." | 1.91 | Taurine depletion impairs cardiac function and affects tolerance to hypoxia and high temperatures in brook char (Salvelinus fontinalis). ( Buldo, EC; Cockshutt, A; Dixon, TM; El, N; Lamarre, SG; MacCormack, TJ; McGaw, SP; Morash, AJ; Otley, NA; Pabody, CM; Parker, KS; Rhyno, EM; Savoie, M, 2023) |
| "Taurine is an important osmolyte in teleost hearts, but its role in stress tolerance, cardiac metabolism, and contractility has not been assessed." | 1.48 | Taurine protects cardiac contractility in killifish, Fundulus heteroclitus, by enhancing sarcoplasmic reticular Ca ( Henry, EF; MacCormack, TJ, 2018) |
| "Taurine is an inhibitory neurotransmitter and is one of the most abundant amino acids present in the mammalian nervous system." | 1.39 | The mechanism of taurine protection against endoplasmic reticulum stress in an animal stroke model of cerebral artery occlusion and stroke-related conditions in primary neuronal cell culture. ( Chen, PC; Gharibani, PM; Ma, Z; Menzie, J; Modi, J; Pan, C; Prentice, H; Tao, R; Wu, JY, 2013) |
| "Compared with the NS group, the anoxia endurance of the zinc sulfate group was increased 33." | 1.33 | [Effects of taurine and zinc on activity of NOS and expression of nNOS in cerebral cortex of acute hypoxic mice]. ( Chen, J; Li, JS; Wang, HR; Zhang, H, 2006) |
| "Taurine depletion was achieved by exposing isolated neonatal cardiomyocytes to medium containing the taurine analog beta-Alanine." | 1.31 | Beneficial effect of taurine depletion on osmotic sodium and calcium loading during chemical hypoxia. ( Kakhniashvili, D; Schaffer, SW; Solodushko, V, 2002) |
| "Taurine release was partially Ca2+-dependent in all cases." | 1.30 | Enhanced taurine release in cell-damaging conditions in the developing and ageing mouse hippocampus. ( Oja, SS; Saransaari, P, 1997) |
| "The effects of anoxia on the brain concentrations of gamma-aminobutyric acid (GABA), glutamate, aspartate, glutamine, alanine, and taurine were measured in the shore crab (Carcinus maenas) and compared with data previously obtained from anoxia-tolerant vertebrates." | 1.29 | Changes in the brain levels of GABA and related amino acids in anoxic shore crab (Carcinus maenas). ( Nilsson, GE; Winberg, S, 1993) |
| "We have previously reported that chronic administration of valproate in developing mice decreased brain aspartic and glutamic acid levels and increased the brain taurine content." | 1.28 | Valproate doubles the anoxic survival time of normal developing mice: possible relevance to valproate-induced decreases in cerebral levels of glutamate and aspartate, and increases in taurine. ( Hauhart, RE; Thurston, JH, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (26.92) | 18.7374 |
| 1990's | 12 (23.08) | 18.2507 |
| 2000's | 14 (26.92) | 29.6817 |
| 2010's | 6 (11.54) | 24.3611 |
| 2020's | 6 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, M | 1 |
| Wang, Y | 1 |
| Meng, Y | 1 |
| Hu, J | 1 |
| Qiao, J | 1 |
| Zhen, J | 1 |
| Liang, D | 1 |
| Fan, M | 1 |
| Sun, Z | 1 |
| Wu, J | 2 |
| Bi, Q | 1 |
| Wang, W | 1 |
| Lu, W | 1 |
| Yang, Y | 1 |
| Gao, S | 1 |
| Sun, X | 1 |
| Azzam, HN | 1 |
| El-Derany, MO | 1 |
| Wahdan, SA | 1 |
| Faheim, RM | 1 |
| Helal, GK | 1 |
| El-Demerdash, E | 1 |
| Dixon, TM | 1 |
| Rhyno, EM | 1 |
| El, N | 1 |
| McGaw, SP | 1 |
| Otley, NA | 1 |
| Parker, KS | 1 |
| Buldo, EC | 1 |
| Pabody, CM | 1 |
| Savoie, M | 1 |
| Cockshutt, A | 1 |
| Morash, AJ | 1 |
| Lamarre, SG | 1 |
| MacCormack, TJ | 2 |
| Haider, F | 1 |
| Falfushynska, HI | 1 |
| Timm, S | 1 |
| Sokolova, IM | 1 |
| Henry, EF | 1 |
| Wang, Q | 1 |
| Huang, H | 1 |
| Huang, Z | 1 |
| Gao, P | 1 |
| Yang, C | 1 |
| Nesvick, CL | 1 |
| Feldman, MJ | 1 |
| Sizdahkhani, S | 1 |
| Liu, H | 1 |
| Chu, H | 1 |
| Yang, F | 1 |
| Tang, L | 1 |
| Tian, J | 1 |
| Zhao, S | 1 |
| Li, G | 1 |
| Heiss, JD | 1 |
| Liu, Y | 2 |
| Zhuang, Z | 1 |
| Xu, G | 1 |
| Benesova, J | 1 |
| Hock, M | 1 |
| Butenko, O | 1 |
| Prajerova, I | 1 |
| Anderova, M | 1 |
| Chvatal, A | 1 |
| Chen, F | 1 |
| Mi, M | 1 |
| Zhang, Q | 1 |
| Wei, N | 1 |
| Chen, K | 1 |
| Xu, H | 1 |
| Yuan, J | 1 |
| Zhou, Y | 1 |
| Lang, H | 1 |
| Yu, X | 1 |
| Wang, B | 1 |
| Wang, J | 1 |
| Tang, Y | 1 |
| Chang, H | 1 |
| Yang, H | 1 |
| Tian, L | 1 |
| Huang, J | 1 |
| Liang, G | 1 |
| Gharibani, PM | 1 |
| Modi, J | 1 |
| Pan, C | 1 |
| Menzie, J | 1 |
| Ma, Z | 1 |
| Chen, PC | 1 |
| Tao, R | 1 |
| Prentice, H | 1 |
| Wu, JY | 1 |
| Schaffer, SW | 2 |
| Pastukh, V | 1 |
| Solodushko, V | 2 |
| Kramer, J | 1 |
| Azuma, J | 1 |
| González, G | 1 |
| Celedón, G | 1 |
| Sandoval, M | 1 |
| González, GE | 1 |
| Ferrer, V | 1 |
| Astete, R | 1 |
| Behn, C | 1 |
| Ørtenblad, N | 1 |
| Young, JF | 1 |
| Oksbjerg, N | 1 |
| Nielsen, JH | 1 |
| Lambert, IH | 1 |
| Amano, H | 1 |
| Maruyama, K | 1 |
| Naka, M | 1 |
| Tanaka, T | 1 |
| PLAYOUST, MR | 1 |
| ISSELBACHER, KJ | 1 |
| Büyükuysal, RL | 1 |
| Wang, HR | 1 |
| Li, JS | 1 |
| Chen, J | 1 |
| Zhang, H | 1 |
| Molchanova, SM | 1 |
| Oja, SS | 3 |
| Saransaari, P | 3 |
| Gavrovskaya, LK | 1 |
| Krylova, IB | 1 |
| Selina, EN | 1 |
| Safonova, AF | 1 |
| Petrova, NN | 1 |
| Sapronov, NS | 1 |
| de Boo, HA | 1 |
| Harding, JE | 1 |
| Hehre, DA | 1 |
| Devia, CJ | 1 |
| Bancalari, E | 1 |
| Suguihara, C | 1 |
| Chesney, RW | 2 |
| Friedman, AL | 1 |
| Albright, PW | 1 |
| Jax, DK | 2 |
| Gingery, R | 1 |
| Gusowski, N | 1 |
| Cooper, MW | 1 |
| Lombardini, JB | 2 |
| Nilsson, GE | 2 |
| Winberg, S | 1 |
| Man'kovs'ka, IM | 1 |
| Seredenko, MM | 1 |
| Vavilova, HL | 1 |
| Kharlamova, OM | 1 |
| Bystriukov, VO | 1 |
| Dudariev, VP | 1 |
| Lanovenko, II | 1 |
| Hoop, B | 2 |
| Beagle, JL | 1 |
| Maher, TJ | 1 |
| Kazemi, H | 3 |
| Wheeler, MD | 1 |
| Ikejema, K | 1 |
| Enomoto, N | 1 |
| Stacklewitz, RF | 1 |
| Seabra, V | 1 |
| Zhong, Z | 1 |
| Yin, M | 1 |
| Schemmer, P | 1 |
| Rose, ML | 1 |
| Rusyn, I | 1 |
| Bradford, B | 1 |
| Thurman, RG | 1 |
| Mankovskaya, IN | 1 |
| Serebrovskaya, TV | 1 |
| Swanson, RJ | 1 |
| Vavilova, GL | 1 |
| Kharlamova, ON | 1 |
| Pessina, F | 1 |
| Matteucci, G | 1 |
| Esposito, L | 1 |
| Gorelli, B | 1 |
| Valoti, M | 1 |
| Sgaragli, G | 1 |
| Kakhniashvili, D | 1 |
| Crass, MF | 1 |
| Young, RS | 1 |
| During, MJ | 1 |
| Aquila, WJ | 1 |
| Tendler, D | 1 |
| Ley, E | 1 |
| Lutz, PL | 1 |
| Nakada, T | 1 |
| Hida, K | 1 |
| Kwee, IL | 1 |
| Tseng, MT | 2 |
| Liu, KN | 2 |
| Boles, CB | 1 |
| Radtke, ND | 1 |
| Radtke, NR | 1 |
| Thurston, JH | 1 |
| Hauhart, RE | 1 |
| Malcangio, M | 1 |
| Bartolini, A | 1 |
| Ghelardini, C | 1 |
| Bennardini, F | 2 |
| Malmberg-Aiello, P | 1 |
| Franconi, F | 2 |
| Giotti, A | 2 |
| Hitzig, BM | 1 |
| Kneussl, MP | 1 |
| Shih, V | 2 |
| Brandstetter, RD | 1 |
| Eldridge, SA | 1 |
| Hilton, FK | 1 |
| Hilton, MA | 1 |
| Lehmann, A | 1 |
| Hagberg, H | 1 |
| Andiné, P | 1 |
| Ellrén, K | 1 |
| Schurr, A | 1 |
| Rigor, BM | 1 |
| Kneussl, M | 1 |
| Hitzig, B | 1 |
| Pappagianopoulos, P | 1 |
| Stendardi, I | 1 |
| Matucci, R | 1 |
| Baccaro, C | 1 |
| Gagliarducci, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
| Glycine | 109.7 | 133.9 | 115.3 |
| Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |
|---|---|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
| Glycine | 104.1 | 111.8 |
| Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
| Glycine | 105.2 | 105.2 | 115.5 |
| Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
| Glycine | 82.0 | 75.6 | 77.7 |
| Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
1 review available for taurine and Anoxemia
| Article | Year |
|---|---|
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
51 other studies available for taurine and Anoxemia
| Article | Year |
|---|---|
Hypoxia induced-disruption of lncRNA TUG1/PRC2 interaction impairs human trophoblast invasion through epigenetically activating Nodal/ALK7 signalling.
Topics: Activin Receptors, Type I; Cell Movement; Cell Proliferation; Female; Humans; Hypoxia; Matrix Metall | 2022 |
Exosomal lncRNA TUG1 derived from human urine-derived stem cells attenuates renal ischemia/reperfusion injury by interacting with SRSF1 to regulate ASCL4-mediated ferroptosis.
Topics: Acute Kidney Injury; Animals; Ferroptosis; Humans; Hypoxia; Ischemia; Kidney; Mice; Mice, Inbred C57 | 2022 |
Taurine protects R28 cells from hypoxia/re-oxygenation-induced damage via regulation of mitochondrial energy metabolism.
Topics: Animals; Cell Line; Energy Metabolism; GTP-Binding Proteins; Hypoxia; Membrane Potential, Mitochondr | 2022 |
Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer.
Topics: Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alph | 2022 |
Taurine depletion impairs cardiac function and affects tolerance to hypoxia and high temperatures in brook char (Salvelinus fontinalis).
Topics: Animals; Hypoxia; Myocytes, Cardiac; Taurine; Temperature; Trout | 2023 |
Effects of hypoxia and reoxygenation on intermediary metabolite homeostasis of marine bivalves Mytilus edulis and Crassostrea gigas.
Topics: Aerobiosis; Amino Acids; Animals; Crassostrea; Energy Metabolism; gamma-Aminobutyric Acid; Homeostas | 2020 |
Taurine protects cardiac contractility in killifish, Fundulus heteroclitus, by enhancing sarcoplasmic reticular Ca
Topics: Animals; Calcium; Cardiotonic Agents; Female; Fundulidae; Hypoxia; Male; Myocardial Contraction; Myo | 2018 |
[Taurine inhibited the apoptosis of glial cells induced by hypoxia].
Topics: Apoptosis; Hypoxia; Neuroglia; RNA, Messenger; Taurine | 2015 |
Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling.
Topics: Animals; Apoptosis; Brain; Case-Control Studies; Cell Cycle; Cell Proliferation; Follow-Up Studies; | 2016 |
Quantification of astrocyte volume changes during ischemia in situ reveals two populations of astrocytes in the cortex of GFAP/EGFP mice.
Topics: Animals; Astrocytes; Cell Size; Cerebral Cortex; Disease Models, Animal; Electric Stimulation; Glial | 2009 |
Taurine buffers glutamate homeostasis in retinal cells in vitro under hypoxic conditions.
Topics: Amino Acid Transport System X-AG; Animals; Buffers; Cell Survival; Cells, Cultured; Fluorescent Anti | 2010 |
Dietary taurine can improve the hypoxia-tolerance but not the growth performance in juvenile grass carp Ctenopharyngodon idellus.
Topics: Adaptation, Physiological; Analysis of Variance; Animals; Carps; Dietary Supplements; Hypoxia; Lipid | 2013 |
The mechanism of taurine protection against endoplasmic reticulum stress in an animal stroke model of cerebral artery occlusion and stroke-related conditions in primary neuronal cell culture.
Topics: Activating Transcription Factor 6; Animals; Apoptosis; Brain Ischemia; Caspase 12; Caspase 3; Cell S | 2013 |
Effect of ischemia, calcium depletion and repletion, acidosis and hypoxia on cellular taurine content.
Topics: Acidosis; Animals; Calcium; Cells, Cultured; Hypoxia; In Vitro Techniques; Male; Myocardial Ischemia | 2002 |
Hypobaric hypoxia-reoxygenation diminishes band 3 protein functions in human erythrocytes.
Topics: Adult; Anion Exchange Protein 1, Erythrocyte; Atmospheric Pressure; Erythrocytes; Fluorescent Dyes; | 2002 |
Reactive oxygen species are important mediators of taurine release from skeletal muscle cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Antioxidants; Butylated Hydroxytoluene; C | 2003 |
Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysis.
Topics: Animals; Base Sequence; Cells, Cultured; Gene Expression Profiling; Gene Targeting; Hypoxia; Lung; M | 2003 |
STUDIES ON THE TRANSPORT AND METABOLISM OF CONJUGATED BILE SALTS BY INTESTINAL MUCOSA.
Topics: Absorption; Bile Acids and Salts; Biological Transport; Cricetinae; Dinitrophenols; Hypoxia; Intesti | 1964 |
Ischemia and reoxygenation induced amino acid release release and tissue damage in the slices of rat corpus striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Brain; Calcium; Citrulline; Corpus Striatum; Female; gamma-Amin | 2004 |
[Effects of taurine and zinc on activity of NOS and expression of nNOS in cerebral cortex of acute hypoxic mice].
Topics: Animals; Cerebral Cortex; Hypoxia; Hypoxia, Brain; Male; Mice; Neuroprotective Agents; Nitric Oxide | 2006 |
Taurine attenuates D-[3H]aspartate release evoked by depolarization in ischemic corticostriatal slices.
Topics: Animals; Aspartic Acid; Brain Ischemia; Cerebral Cortex; Corpus Striatum; Dose-Response Relationship | 2006 |
Antihypoxic properties of taurinamide derivatives: the experimental study.
Topics: Acetylcholinesterase; Alkanesulfonic Acids; Amides; Animals; Antioxidants; Cochlea; Female; Guinea P | 2006 |
Taurine as a marker for foetal wellbeing?
Topics: Amino Acids; Animals; Biomarkers; Disease Models, Animal; Female; Fetal Death; Fetal Development; Fe | 2007 |
Brainstem amino acid neurotransmitters and ventilatory response to hypoxia in piglets.
Topics: Acid-Base Equilibrium; Amino Acids; Animals; Animals, Newborn; Aspartic Acid; Blood Pressure; Carbon | 2008 |
Studies on the renal handling of taurine: changes during maturation and after altered dietary intake.
Topics: Aging; Animals; Bucladesine; Dietary Proteins; Female; Hypoxia; Kidney Tubules; Kinetics; Male; Preg | 1981 |
Elevated blood taurine levels after myocardial infarction of cardiovascular surgery: is there any significance?
Topics: Animals; Cardiac Surgical Procedures; Coronary Artery Bypass; Creatine Kinase; Dogs; Heart; Humans; | 1981 |
Changes in the brain levels of GABA and related amino acids in anoxic shore crab (Carcinus maenas).
Topics: Alanine; Amino Acids, Branched-Chain; Animals; Aspartic Acid; Brachyura; Brain Chemistry; gamma-Amin | 1993 |
Enhanced taurine release in cell-damaging conditions in the developing and ageing mouse hippocampus.
Topics: Aging; Animals; Animals, Newborn; Brain Ischemia; Cell Survival; Female; Hippocampus; Hypoxia; Male; | 1997 |
Release of endogenous glutamate, aspartate, GABA, and taurine from hippocampal slices from adult and developing mice under cell-damaging conditions.
Topics: Aging; Animals; Aspartic Acid; Brain Ischemia; Female; gamma-Aminobutyric Acid; Glutamic Acid; Hippo | 1998 |
[The antioxidant action of taurine in acute hypoxic hypoxia].
Topics: Acute Disease; Animals; Antioxidants; Brain; Drug Evaluation, Preclinical; Glutathione; Heart; Hypox | 1998 |
[Changes in the oxygen-binding properties of the blood in white rats under the influence of hypoxia and its pharmacological correction].
Topics: Acute Disease; Animals; Antioxidants; Butylated Hydroxytoluene; Chronic Disease; Drug Evaluation, Pr | 1999 |
Brainstem amino acid neurotransmitters and hypoxic ventilatory response.
Topics: Animals; Brain Stem; Denervation; gamma-Aminobutyric Acid; Glutamic Acid; Hypoxia; Male; Microdialys | 1999 |
Mechanisms of taurine antihypoxic and antioxidant action.
Topics: Animals; Antioxidants; Disease Models, Animal; Drug Evaluation, Preclinical; Hypoxia; Injections, In | 2000 |
Protection of intrinsic nerves of guinea-pig detrusor strips against anoxia/glucopenia and reperfusion injury by taurine.
Topics: Aminoethylphosphonic Acid; Animals; Atropine; Electric Stimulation; Evoked Potentials; Glucose; Guin | 2000 |
Beneficial effect of taurine depletion on osmotic sodium and calcium loading during chemical hypoxia.
Topics: Animals; Apoptosis; beta-Alanine; Calcium; Cells, Cultured; Culture Media, Serum-Free; Heart; Hydrog | 2002 |
Development aspects of renal beta-amino acid transport II. Ontogeny of uptake and efflux processes and effect of anoxia.
Topics: Animals; Animals, Newborn; Biological Transport; Bucladesine; Hypoxia; Kidney Cortex; Nucleotides, C | 1979 |
Release of tissue taurine from the oxygen-deficient perfused rat heart.
Topics: Animals; Coronary Disease; Hypoxia; In Vitro Techniques; Male; Myocardium; Perfusion; Rats; Taurine; | 1978 |
Hypoxia increases extracellular concentrations of excitatory and inhibitory neurotransmitters in subsequently induced seizure: in vivo microdialysis study in the rabbit.
Topics: Animals; Aspartic Acid; Bicuculline; Brain; Dialysis; Electroencephalography; gamma-Aminobutyric Aci | 1992 |
Release of inhibitory neurotransmitters in response to anoxia in turtle brain.
Topics: Alanine; Animals; Brain; Dialysis; Electrophysiology; Extracellular Space; gamma-Aminobutyric Acid; | 1991 |
pH-lactate dissociation during anoxic insult: taurine effect.
Topics: Adenosine Triphosphate; Animals; Brain Chemistry; Hydrogen-Ion Concentration; Hypoxia; Lactates; Mag | 1991 |
Mitochondrial stability in taurine perfused, hypoxic bovine eye.
Topics: Animals; Cattle; Electroretinography; Eye; Hypoxia; Mitochondria; Perfusion; Retina; Taurine | 1990 |
Facilitated ERG recovery in taurine-treated bovine eyes, an ex vivo study.
Topics: Animals; Cattle; Female; Hypoxia; In Vitro Techniques; Membrane Potentials; Photic Stimulation; Reti | 1990 |
Valproate doubles the anoxic survival time of normal developing mice: possible relevance to valproate-induced decreases in cerebral levels of glutamate and aspartate, and increases in taurine.
Topics: Animals; Animals, Suckling; Aspartic Acid; Body Weight; Brain; Glucose; Glutamates; Hypoxia; Mice; T | 1989 |
Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia.
Topics: Amnesia; Animals; Anticonvulsants; Avoidance Learning; Hypoxia; Injections, Intraventricular; Learni | 1989 |
Brain amino acid concentrations during diving and acid-base stress in turtles.
Topics: Acid-Base Imbalance; Animals; Brain; Diving; Female; gamma-Aminobutyric Acid; Hypercapnia; Hypoxia; | 1985 |
Effect of hypoxic hypoxia on taurine concentrations in ventricles of mouse hearts.
Topics: Animals; Atmosphere Exposure Chambers; Body Weight; Cardiomegaly; Chromatography, High Pressure Liqu | 1985 |
Taurine and neuronal resistance to hypoxia.
Topics: Animals; Brain; Hypoxia; Models, Neurological; Neurons; Taurine | 1988 |
The mechanism of neuronal resistance and adaptation to hypoxia.
Topics: Adaptation, Physiological; Age Factors; Amino Acids, Sulfur; Animals; Animals, Newborn; Brain; Brain | 1987 |
[A model of the central control of respiration].
Topics: Acid-Base Equilibrium; Animals; Chemoreceptor Cells; Diving; gamma-Aminobutyric Acid; Hypercapnia; H | 1986 |
A protective effect of taurine on "hypoxic" and "reoxygenated" guinea pig heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Guinea Pigs; Heart; Hypoxia; In Vitr | 1985 |
[Therapeutic possibilities of a sulfurated amino acid in hypoxic erythrocytosis].
Topics: Humans; Hypoxia; Polycythemia; Taurine | 1971 |